3H Biomedical AB
www.3hbiomedical.com3H Biomedical is an innovative life-science company that discovers, develops and distributes human cell-based products and technologies for life science research, drug development and tissue engineering. We take pride in our contribution to improving human health and environment. Our mission is to help scientists be more productive, more competitive and more innovative. Serving the global research community, biotech sector and pharmaceutical industry. We supply more than 260 different types of primary human cells, media and cell-based products. R&D projects: EUROSTARS: PREVAIL Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer. The PREVAIL project will deliver a first-in-class targeted therapeutic for treatment of triple negative breast cancer (TNBC). SEAL OF EXCELLENCE Next generation of targeted dendritc cell vaccine for cancer treatment, a therapeutic cancer vaccine technology platform. We are actively seeking partners in the pharmaceutical industry and clinical centres in order to co-develop our patented vaccine technology.
Read more3H Biomedical is an innovative life-science company that discovers, develops and distributes human cell-based products and technologies for life science research, drug development and tissue engineering. We take pride in our contribution to improving human health and environment. Our mission is to help scientists be more productive, more competitive and more innovative. Serving the global research community, biotech sector and pharmaceutical industry. We supply more than 260 different types of primary human cells, media and cell-based products. R&D projects: EUROSTARS: PREVAIL Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer. The PREVAIL project will deliver a first-in-class targeted therapeutic for treatment of triple negative breast cancer (TNBC). SEAL OF EXCELLENCE Next generation of targeted dendritc cell vaccine for cancer treatment, a therapeutic cancer vaccine technology platform. We are actively seeking partners in the pharmaceutical industry and clinical centres in order to co-develop our patented vaccine technology.
Read moreCountry
City (Headquarters)
Uppsala
Industry
Employees
1-10
Founded
2004
Estimated Revenue
$1 to $1,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Executive Officer
Email ****** @****.comPhone (***) ****-****Owner
Email ****** @****.comPhone (***) ****-****